A Phase 3 interventional study of BD0801 and Paclitaxel in Ovarian Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 55 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 392 studies in Ovarian Neoplasms with a site in China — 198 open to participants now, 231 under way, 35 of them phase 3. Ovarian Neoplasms · China.
Among the 392 studies in Ovarian Neoplasms with a site in China, this one is the 39th largest by enrollment of the 319 interventional ones that give a count, is one of 44 that started in 2021, is one of 52 in phase 3, and was the 130th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →198 of the 392 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18+ · Women only
Chinese PLA General Hospital · Sites in China
Ages 18–75 · Women only
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Phrontline Biopharma · Sites in China, United States
Ages 18+
AstraZeneca · Sites in China, United States, Australia and 10 more countries
Ages 18+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
392 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 123 · Phase 2 164 · Phase 3 57 · Phase 4 3
First in 2005; this study’s year is marked. 44 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 421 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 83 across the 319 interventional studies, 200 across the 73 observational. Of the 75 that completed or were terminated, 12 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 392 have an industry lead sponsor. The 10 most frequent:
This study is registered under Jiangsu Simcere Pharmaceutical Co., Ltd., one of the names counted as Simcere Pharmaceutical Group Limited. Under that name alone:
Jiangsu Simcere Pharmaceutical Co., Ltd. is the lead sponsor of 78 studies on the registry; 14 are open to participants now.
Simcere Pharmaceutical Group Limited has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
63 of the studies in Ovarian Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06855069Phase 3Hansoh BioMedical R&D CompanyHS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | 2027-03-07 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT06828354Phase 3Jiangsu HengRui Medicine Co., Ltd.A Study of SHR-A1811 in Subjects With Ovarian Cancer | 2027-05 |
| NCT07604766Phase 3GenmabAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China | 2027-09 |
Add all 63 to your calendar (.ics) → With an account.
Among the 392 studies in Ovarian Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance. In patients with platinum-resistant or refractory ovarian cancer, effective treatment options are limited and the prognosis is very poor. Angiogenesis is essential for tumor growth and metastasis, and VEGF/VEGF receptor(VEGFR) signaling pathway is the most promising angiogenic target. This study aim to assess the efficacy and safety of the combination BD0801 and chemotherapy in patients with platinum-resistant recurrent ovarian cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BD0801 is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
Drug: BD0801 · Drug: Paclitaxel · Drug: Topotecan · Drug: doxorubicin liposome
Placebo is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.
Drug: Paclitaxel · Drug: Placebo · Drug: Topotecan · Drug: doxorubicin liposome
Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
Progression free survival(PFS) by blinded independent review committee(BIRC)
PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the IRC according to the RECIST 1.1 criteria
Time frame: 2 year
Overall Survival (OS)
OS is the time interval from the date of randomization to death from any cause.
Time frame: 2.5 year
PFS by investigator
PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST1.1 criteria
Time frame: 2 year
Objective Response Rate (ORR) by investigator
Proportion of subjects who have a complete or partial response relative to baseline as assessed by investigator according to RECIST 1.1 criteria
Time frame: 2 year
Disease Control Rate (DCR) by investigator
Proportion of subjects who have a complete or partial response, or stable disease relative to baseline as assessed by investigator according to RECIST 1.1 criteria
Time frame: 2 year
Objective Response Rate (DOR) by investigator
Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.
Time frame: 2 year
ORR by BIRC
Proportion of subjects who have a complete or partial response relative to baseline as assessed by BIRC according to RECIST 1.1 criteria
Time frame: 2 year
DCR by BIRC
Proportion of subjects who have a complete or partial response, or stable disease relative to baseline as assessed by BIRC according to RECIST 1.1 criteria
Time frame: 2 year
DOR by BIRC
Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.
Time frame: 2 year
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0
Time frame: 2.5 year
Quality Of Life (QoL)
use European Organisation for Research and Treatment of Cance(EORTC)- QLQ-C30 questionnaire
Time frame: 2.5 year
Quality Of Life (QoL)
use EORTC-QLQ-OV28 questionnaire
Time frame: 2.5 year
Serum drug concentrations of BD0801
Serum drug concentrations of BD0801 will be calculated.
Time frame: 2 year
rate of immunogenicity positive reaction
Time frame: 2 year
duration of immunogenicity positive reaction
Time frame: 2 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Dec 2023, 29 months.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 29 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suvemcitug
Jiangsu Simcere Pharmaceutical Co., Ltd. →